Multicenter Clinical Trial for Development of Guidelines of Adequate Blood Pressure Lowering in the Subacute Ischemic Stroke Patients Due to Intracranial Atherosclerosis
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Brain Ischemia
- Sponsor
- Asan Medical Center
- Enrollment
- 132
- Locations
- 16
- Primary Endpoint
- Ischemic Lesion Volume Change in the Whole Forebrain on Fluid Attenuation Inversion Recovery (FLAIR) Magnetic Resonance Imaging (MRI)
- Status
- Terminated
- Last Updated
- 9 years ago
Overview
Brief Summary
To develop adequate blood pressure (BP) lowering strategy after subacute ischemic stroke patients with symptomatic severe intracranial atherosclerosis.
Primary hypothesis of this study is that aggressive BP control (lowering systolic BP between 110mmHg and 120mmHg) will not increase the ischemic lesion volumes in hemisphere compared to modest BP lowering (lowering systolic BP between 130mmHg and 140mmHg) in the patients with symptomatic severe intracranial atherosclerosis.
Detailed Description
The benefits of BP lowering in the prevention of primary and secondary prevention of stroke is established well, although absolute target BP level is uncertain. Current guidelines defined the normal BP as \<120/80mmHg and recommend individualized target BP level. Large well performed stroke prevention trials consistently showed that reduction of 10/5mmHg in patients with systolic BP below 140mmHg had clear benefits in the prevention of cardiovascular events. However, we have a dilemma about BP control in the patients with severe intracranial atherosclerosis. Aggressive BP control will be more effective in the prevention of overall cardiovascular events than modest BP control, but aggressive BP control will reduce cerebral perfusion in the territory of severe intracranial disease and may increase the risk of ischemic damage. The study will try to reveal aggressive BP control in the patients with symptomatic severe intracranial atherosclerosis is not increase ischemic lesion volume in hemisphere to compare modest BP control.
Investigators
Sun U. Kwon
department of neurology
Asan Medical Center
Eligibility Criteria
Inclusion Criteria
- •acute symptomatic ischemic stroke having relevant lesion on DWI(Diffusion weighted image) MRI 7 days after and 42 days within onset.
- •relevant stenosis(more than 50%) or occlusion from MCA(middle cerebral artery)(M1) to distal of ICA(internal carotid artery ) on MR(Magnetic resonance) angiogram or CT angiogram.
- •mean systolic blood pressure\>=140mmHg or taking antihypertensive drug on screening.
Exclusion Criteria
- •taking more than 3 antihypertensive drugs and mean systolic blood pressure\>=150mmHg on screening.
- •history of recent thrombolysis but stenosis or occlusion remained after thrombolysis.
- •evidence of orthostatic hypotension
- •suspicious embolic cerebrovascular stenosis
- •planned state of cerebrovascular surgery or angioplasty or stent 7 months within screening.
- •severe stroke-NIHSS\>=16
- •mean systolic blood pressure\>=200mmHg which is not able to control on screening.
- •abnormal blood test finding (abnormal LFT(liver function test), anemia, renal insufficiency)
- •pregnant or breast-feeding
- •severe stroke sequela or medical problem
Outcomes
Primary Outcomes
Ischemic Lesion Volume Change in the Whole Forebrain on Fluid Attenuation Inversion Recovery (FLAIR) Magnetic Resonance Imaging (MRI)
Time Frame: Screening to 24 weeks
The difference between final ischemic lesions volume and base ischemic lesions of both hemisphere on FLAIR MRI
Secondary Outcomes
- Change of the Ischemic Lesion Volume in Cerebral Hemisphere on FLAIR From Screening to Week 24 in FAS Population(24 weeks)
- The Number of Patients With New Ischemic Lesion in the Whole Forebrain on FLAIR MRI(24 weeks)
- Number of Participants With Cardiovascular Events From Screening to Week 24 in ITT Population.(24 weeks)
- Total Number of Cardiovascular Events Form Screening to Week 24 in ITT Population.(24 Week)
- Number of Participants With Vascular Death From Screening to Week 24 in ITT Population.(24 Weeks)
- Number of Participants With Adverse Events(24 Weeks)